XiVE® CAD/CAM Bridges (Abutment-supported/ Implant-supported) (XiCC)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dentsply Implants Manufacturing GmbH
ClinicalTrials.gov Identifier:
NCT01522365
First received: January 23, 2012
Last updated: May 22, 2014
Last verified: May 2014

January 23, 2012
May 22, 2014
November 2011
December 2016   (final data collection date for primary outcome measure)
Mean change of bone level [ Time Frame: 0, 12, 24 months ] [ Designated as safety issue: No ]

Intra-oral radiographs from implant insertion and at time for prosthesis insertion as well as from 1 and 2-year follow-up visits (calculated from the time of loading) should be taken for evaluation of bone level. All radiographs will be examined by an independent dentist.

For the purpose of this examination XCP film holder (DENTSPLY Rinn, 1212 Abbott Drive, Elgin, Illinois 60123-1819, USA) are individualized for each subject and for each x-ray.

Same as current
Complete list of historical versions of study NCT01522365 on ClinicalTrials.gov Archive Site
Sulcus-fluid-flow-rate [ Time Frame: 6 weeks, 6, 12, 24 months ] [ Designated as safety issue: No ]
The evaluation of the sulcus fluid flow rate (SFFR) is a common method for the objective definition of the gingiva inflammation level in clinical research. The SFFR is measured with the electronic sulcus fluid hygrometer, Periotron model 600 A No. 700702 (Harco Electronics Ltd., Canada) and always as the first procedure in order not to be influenced by other investigation parameters.
Same as current
Not Provided
Not Provided
 
XiVE® CAD/CAM Bridges (Abutment-supported/ Implant-supported)
A Randomized, Prospective, International, Multi-center Clinical Study to Evaluate the Peri-implant Tissue Outcome of Abutment-supported XiVE® CAD/CAM Supra-structures and Directly Implant-supported XiVE® CAD/CAM Supra-structures (Split-mouth) in Partly Edentulous Human Subjects.

This study has been designed in order to collect data with regards to the peri-implant tissue outcome of abutment-supported restoration and direct implant-fixed restoration. Therefore a small group of subjects with partly edentulous maxilla is selected to show that both techniques are efficient and safe and to show comparable peri-implant tissue outcome for both methods. At the time of impression forming for each centre treatment A (= abutment-supported XiVE® CAD/CAM supra-structure) and B (= direct implant-fixed XiVE® CAD/CAM supra-structure) is assigned to the left and right side of the maxilla by being randomized at the time of impression forming.

The planned study profile is to assess the peri-implant tissue outcome of abutment-supported restoration and direct implant-fixed restoration. Two treatments, Treatment A which is the abutment-fixed supra-structure and Treatment B, the direct implant-fixed restoration, are assessed within the scope of this clinical investigation.

Treatment A: The XiVE® CAD/CAM supra-structure is fixed on abutments. The effect of platform-switching which is discussed intensely in the scientific literature is used in order to shift away the connection between implant and supra-construction (interface) from the implant edge and peri-implant tissue and towards the implant centre. However, the implant-abutment-connection area is a potential entry port for micro-organisms which have direct influence on the state of the peri-implant hard and soft tissue and consequently on the long-term prosthetic and implant success [8]. By using an abutment as a connector between implant and supra-structure implies the generation of one more micro-gap (between supra-structure and abutment) and possible retention of microbial plaque though located above the hard tissue level.

Treatment B: The XiVE® CAD/CAM supra-structure is fixed directly on the implants. In contrary to treatment A, only one entry port (micro-gap) for micro-organisms exists: The interface between supra-construction and implant. So, there is one main point where the initial force has main influence on the implant and the peri-implant tissue [8-10]. Besides, this interface lies directly on the implant shoulder level and by that on the osseous level. There is no displacement of the transitional area to the implant centre.

This study has been designed in order to collect data with regards to the CAD/CAM system used on the DENTSPLY Friadent implant system XiVE®. In particular, the peri-implant tissue outcome of abutment-supported restoration and direct implant-fixed restoration will be evaluated. Therefore a small group of subjects with partly edentulous jaw is selected to show that both techniques are efficient and safe and to demonstrate the non-inferiority with regards to the peri-implant tissue outcome for any of both techniques.

Each subject will receive both treatments, treatment A on the one site of the maxilla and treatment B on the other. The randomization method which finally defines which subject receives one treatment on the left maxilla region and the other on the right maxilla area or vice versa is described in section 5.1.

In conclusion, both treatments might have pros and cons which may affect the peri-implant tissue outcome.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Partly Edentulous Maxilla
  • Device: Abutment-supported XiVE CAD/CAM bridge
    One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
  • Device: Implant-supported XiVE CAD/CAM bridge
    One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
  • Active Comparator: Abutment-supported XiVE CAD/CAM bridge
    After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
    Intervention: Device: Abutment-supported XiVE CAD/CAM bridge
  • Active Comparator: Implant-supported XiVE CAD/CAM bridge
    After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
    Intervention: Device: Implant-supported XiVE CAD/CAM bridge
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
March 2017
December 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject > 18 years.
  2. Female subject of child-bearing potential must use reliable methods of contraception.
  3. Subject has partly edentulous maxilla (free-end or large gap in posterior area on both sides).
  4. For all implants immobility and clear percussion sound is applicable.
  5. The subject is healthy and compliant with good oral hygiene.
  6. Favorable and stable occlusal relationship between the remaining teeth.
  7. Subject must be reliable, cooperative, and in the opinion of the Investigator, likely to be compliant with study procedures.
  8. Subject provides written informed consent signed and dated prior to entering the study.
  9. Implantation of XiVE® implants at least 3 months ago.
  10. XiVE® implants have been placed primary stable by considering sufficient horizontal and vertical bone dimension.

Exclusion Criteria:

  1. Subject has a history of drug abuse, addiction to medication or alcohol abuse within the previous year.
  2. Subject with planned or performed head and neck radiation.
  3. Known unavailability of subject for FU Visit(s).
  4. Subject has - in the opinion of the investigator - any systemic metabolic disorder or bone disorder or is taking medication that compromises or might have compromised post-operative tissue regeneration or osseointegration.
  5. Subject has major bone defects in the implantation area.
  6. Subject is taking medication that compromises or might have compromised post-operative healing and/or osseointegration (e. g. bisphosphonates).
  7. Subject exhibits an oral infection.
  8. Subject has received any investigational drug within 30 days prior to screening.
  9. Severe bruxing.
  10. Subject has a clinically significant or unstable medical or physiological condition.
  11. Female subject is pregnant or lactating or intends to become pregnant during the course of the study.
  12. Subject is not willing to participate in the study or not able to understand the content of the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany,   United Kingdom
 
NCT01522365
DF0909-1-272-1x-1
No
Dentsply Implants Manufacturing GmbH
Dentsply Implants Manufacturing GmbH
Not Provided
Principal Investigator: Manfred Wichmann, Prof. Dr. Erlangen University Hospital
Principal Investigator: Thomas Dietrich, Prof. Dr. Dr. Birmingham University, School of Dentistry
Dentsply Implants Manufacturing GmbH
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP